We use cookies to customise content for your subscription and for analytics. If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In March 1998, GSK notified its Spanish dual pricing arrangements to the European Commission in order to obtain a declaration that these arrangements were not caught by the prohibition of anticompetitive agreements laid down in Article 81(1) EC or, failing that, an exemption in light of the efficiency gains obtained by countering parallel trade in pharmaceutical products
